<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325817</url>
  </required_header>
  <id_info>
    <org_study_id>BEYOND</org_study_id>
    <nct_id>NCT02325817</nct_id>
  </id_info>
  <brief_title>Bingo Drug-eluting Balloon in Bifurcation</brief_title>
  <official_title>A Multicenter, Superior, Randomized Controlled Clinical Trial to Observe the Safety and Efficacy of Bingo Drug-eluting Balloon vs. Yinyi Balloon Dilatation Catheter in the Treatment of Patients With Bifurcation Stenosis Lesions of Coronary Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yinyi(Liaoning) Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yinyi(Liaoning) Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to observe and evaluate the safety and efficacy of Bingo drug-eluting balloon&#xD;
      in the treatment of patients with bifurcation lesions of coronary artery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2014</start_date>
  <completion_date type="Actual">January 13, 2017</completion_date>
  <primary_completion_date type="Actual">November 29, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion Stenosis (diameter, %)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>cardiac death, target vessel MI, TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>all-cause death, MI, stroke and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal MI, thrombosis</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>1, 6 and 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Bifurcation Lesions</condition>
  <condition>Drug Eluting Balloon</condition>
  <arm_group>
    <arm_group_label>Drug-eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treat the side branch of bifurcation lesion with drug-eluting balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncoated balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treat the side branch of bifurcation lesion with uncoated balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting balloon</intervention_name>
    <description>Treat the side branch of bifurcation lesion with drug-eluting balloon</description>
    <arm_group_label>Drug-eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uncoated ballloon</intervention_name>
    <description>Treat the side branch of bifurcation lesion with uncoated balloon</description>
    <arm_group_label>Uncoated balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female ages 18-80 years old&#xD;
&#xD;
          2. Patients with asymptomatic myocardial ischemia symptom, stable or unstable angina&#xD;
             pectoris or old myocardial infarction&#xD;
&#xD;
          3. Patients with bifurcation lesions of coronary artery observed by angiography.&#xD;
&#xD;
          4. The main branch of the vessels are suitable for PCI and stent therapy, and the side&#xD;
             branch are intended to implement the kissing dilatation without considering dual stent&#xD;
             implantation.&#xD;
&#xD;
          5. De Novo bifurcation lesions and diameter stenosis are not less than70%;&#xD;
&#xD;
          6. Referenced vessel diameters range from 1.25mm to 5.0mm, and lesions range are not more&#xD;
             than 40mm&#xD;
&#xD;
          7. Residual stenosis are not more than 50% after predilatation;&#xD;
&#xD;
          8. Patients who understand the purpose of this trial, voluntary and sign informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Heavily calcified lesions which cannot be dalatated successfully, and the lesions&#xD;
             which are not suitable by balloon angioplasty&#xD;
&#xD;
          2. Left main coronary artery lesions without protection or related bifurcation lesions&#xD;
&#xD;
          3. Patients with severe heart failure symptoms (above NYHA III) or Left ventricular&#xD;
             ejection fraction (LVEF) below 35% (ultrasound or left ventricular angiography)&#xD;
&#xD;
          4. Impairment of the renal function preoperative: Serum creatinine above 2.0mg/dlï¼›&#xD;
&#xD;
          5. Patients with hemorrhagic tendency, the history of active digestive ulcers, the&#xD;
             history of subarachnoid hemorrhage cerebral hemorrhage, antiplatelet and anticoagulant&#xD;
             therapy contraindication and unable to anticoagulant therapy;&#xD;
&#xD;
          6. Patients who are allergic to aspirin, ticagrelor, clopidogrel, ticlopidine, heparin,&#xD;
             contrast agent and paclitaxel, and cannot 1-year tolerate dual antiplatelet therapy&#xD;
             (aspirin + clopidogrel or ticagrelor)&#xD;
&#xD;
          7. Patients whose expected lives are less than 1 year;&#xD;
&#xD;
          8. Patients who are considered to have poor compliance and cannot complete the trial in&#xD;
             accordance with requirements.&#xD;
&#xD;
          9. In-stent restenosis lesions&#xD;
&#xD;
         10. Patients who are enrolled in this trial and need stent therapy due to vascular&#xD;
             laceration or severe stenosis, and those patients are calculated as fall off cases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 20, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifurcation Lesions</keyword>
  <keyword>drug eluting balloon</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>drug coated balloon</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

